Iacovino Marialucia, Ciaramella Vincenza, Paragliola Fernando, Suarato Gabriella, Busiello Gesualdina, Sparano Francesca
Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy.
Explor Target Antitumor Ther. 2020;1(6):391-400. doi: 10.37349/etat.2020.00024. Epub 2020 Dec 28.
Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor () oncogene addicted tumor. In these patients, despite the clear benefits of tyrosine kinase inhibitors therapy, the development of acquired resistance and progressive disease is inevitable in most cases and liquid biopsy is important for molecular characterization at resistance and, being non-invasive, may be useful for disease monitoring. In this review, the authors will focus on the applications of liquid biopsy in -mutated non small cells lung cancer at diagnosis, during treatment and at progression, describing available data and possible future scenarios.
液体活检已成为一种微创方法，可替代肿瘤组织分析用于肺癌患者的管理，尤其是对于依赖表皮生长因子受体（EGFR）致癌基因的肿瘤。在这些患者中，尽管酪氨酸激酶抑制剂治疗有明显益处，但在大多数情况下，获得性耐药和疾病进展的发生是不可避免的，而液体活检对于耐药时的分子特征分析很重要，并且由于其非侵入性，可能对疾病监测有用。在本综述中，作者将重点关注液体活检在EGFR突变的非小细胞肺癌诊断、治疗期间和疾病进展时的应用，描述现有数据和可能的未来情况。
